Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
GNLX
Upturn stock ratingUpturn stock rating

Genelux Corporation Common Stock (GNLX)

Upturn stock ratingUpturn stock rating
$3.41
Last Close (24-hour delay)
Profit since last BUY5.96%
upturn advisory
SELL
SELL since 2 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: GNLX (1-star) is a SELL. SELL since 2 days. Profits (5.96%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $18

1 Year Target Price $18

Analysts Price Target For last 52 week
$18 Target price
52w Low $1.95
Current$3.41
52w High $5.88

Analysis of Past Performance

Type Stock
Historic Profit -13.59%
Avg. Invested days 23
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 128.81M USD
Price to earnings Ratio -
1Y Target Price 18
Price to earnings Ratio -
1Y Target Price 18
Volume (30-day avg) 5
Beta -0.35
52 Weeks Range 1.95 - 5.88
Updated Date 08/15/2025
52 Weeks Range 1.95 - 5.88
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.85

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.22
Actual -0.2

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -52.14%
Return on Equity (TTM) -98.73%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 102541440
Price to Sales(TTM) 12362.41
Enterprise Value 102541440
Price to Sales(TTM) 12362.41
Enterprise Value to Revenue 6302.51
Enterprise Value to EBITDA -327.19
Shares Outstanding 37773400
Shares Floating 33302151
Shares Outstanding 37773400
Shares Floating 33302151
Percent Insiders 11.4
Percent Institutions 21.51

ai summary icon Upturn AI SWOT

Genelux Corporation Common Stock

stock logo

Company Overview

overview logo History and Background

Genelux Corporation Common Stock was founded in 2005, focusing on biotechnology. Early milestones involved pre-clinical trials. They went public in 2015 and have since focused on clinical development of their oncolytic virus therapies.

business area logo Core Business Areas

  • Oncolytic Virus Immunotherapy: Development and commercialization of oncolytic viruses to treat cancer. This includes preclinical and clinical development programs.
  • Proprietary Platform Technology: Genelux has developed a proprietary platform for the design and engineering of oncolytic viruses.

leadership logo Leadership and Structure

The leadership team consists of a CEO with extensive biotech experience, a CFO overseeing financial strategy, and a Chief Scientific Officer leading research and development. The organizational structure is functional, with departments for research, clinical development, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Olvi-Vec (vusolimogene oderparepvec): An oncolytic vaccinia virus designed to selectively infect and destroy cancer cells. It is currently in Phase 3 clinical trials. Market share is currently 0% as it awaits FDA approval. Competitors include companies developing other oncolytic virus therapies, such as Amgen (T-Vec).

Market Dynamics

industry overview logo Industry Overview

The oncolytic virus therapy market is rapidly growing, driven by increasing cancer rates and the limitations of traditional cancer treatments. The industry is characterized by intense research and development and increasing regulatory approvals.

Positioning

Genelux is positioned as an emerging player in the oncolytic virus therapy market, with a promising platform technology and a lead product in late-stage clinical development. Their competitive advantage lies in the unique properties of their oncolytic virus.

Total Addressable Market (TAM)

The global oncolytic virus therapy market is projected to reach $887 million by 2028. Genelux is positioned to capture a significant portion of this market if Olvi-Vec is approved, primarily targeting cancers with limited treatment options.

Upturn SWOT Analysis

Strengths

  • Proprietary oncolytic virus platform
  • Lead product in late-stage clinical trials
  • Experienced management team
  • Strong intellectual property position

Weaknesses

  • Limited financial resources
  • Dependence on a single product
  • Lack of commercialization experience
  • High regulatory risk

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline through new oncolytic virus candidates
  • Expansion into new cancer indications
  • Positive clinical trial results

Threats

  • Failure to obtain regulatory approval
  • Competition from other oncolytic virus therapies
  • Adverse events in clinical trials
  • Changes in the regulatory landscape

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • MRTX
  • BNTX

Competitive Landscape

Genelux competes with larger pharmaceutical companies that have established oncolytic virus therapies. Their competitive advantage will depend on the efficacy and safety profile of Olvi-Vec compared to existing treatments.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited to the progression of their lead product through clinical trials.

Future Projections: Future growth is highly dependent on the successful commercialization of Olvi-Vec. Analyst projections vary based on regulatory approval and market penetration.

Recent Initiatives: Recent initiatives include enrolling patients in Phase 3 clinical trials and seeking partnerships for commercialization.

Summary

Genelux is a development-stage biotech company with a promising oncolytic virus platform. Their success hinges on positive Phase 3 clinical trial results and regulatory approval of Olvi-Vec. They face significant financial and competitive challenges as they compete with larger, more established players in the market. Investors need to monitor the clinical trial progress, financial runway, and competitive landscape carefully.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Analyst Reports
  • Industry Research Reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data, which is subject to change. Investing in biotech companies is inherently risky, and investors should carefully consider their own risk tolerance and financial circumstances before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Genelux Corporation Common Stock

Exchange NASDAQ
Headquaters Westlake Village, CA, United States
IPO Launch date 2023-01-26
Chairman, CEO & President Mr. Thomas D. Zindrick J.D.
Sector Healthcare
Industry Biotechnology
Full time employees 24
Full time employees 24

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.